Polyhydroxycurcuminoids but not curcumin upregulate neprilysin and can be applied to the prevention of Alzheimer's disease

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Chen, Po Ting ^a,b   Chen, Zih Ten ^b   Hou, Wen Chi ^c   Yu, Lung Chih ^a   Chen, Rita P Y ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b INSTITUTE OF BIOLOGICAL CHEMISTRY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CURCUMIN; MEMBRANE METALLOENDOPEPTIDASE;

ALZHEIMER DISEASE; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; MOUSE; TRANSGENIC MOUSE; TUMOR CELL LINE; UPREGULATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CELL LINE, TUMOR; CURCUMIN; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, TRANSGENIC; NEPRILYSIN; UP-REGULATION;

EID: 84978859488     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep29760     Document Type: Article

References (47)

1. Lannfelt, L. et al. Perspectives on future Alzheimer therapies: amyloid-beta protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease. Alzheimers Res. Ther. 6, 16 (2014).
2. Moreth, J., Mavoungou, C. & Schindowski, K. Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets? Immun. Ageing 10, 18 (2013).
3. Iwata, N., Higuchi, M. & Saido, T. C. Metabolism of amyloid-b peptide and Alzheimer's disease. Pharmacol. Therapeut. 108, 129-148 (2005).
4. Wang, D. S., Iwata, N., Hama, E., Saido, T. C. & Dickson, D. W. Oxidized neprilysin in aging and Alzheimer's disease brains. Biochem. Biophys. Res. Commun. 310, 236-241 (2003).
5. Hellstrom-Lindahl, E., Ravid, R. & Nordberg, A. Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: inverse correlation with A beta levels. Neurobiol. Aging 29, 210-221 (2008).
6. Yasojima, K., McGeer, E. G. & McGeer, P. L. Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. Brain Res. 919, 115-121 (2001).
7. Caccamo, A., Oddo, S., Sugarman, M. C., Akbari, Y. & LaFerla, F. A. Age-and region-dependent alterations in Ab-degrading enzymes: implications for Ab-induced disorders. Neurobiol. Aging 26, 645-654 (2005).
8. Iwata, N., Takaki, Y., Fukami, S., Tsubuki, S. & Saido, T. C. Region-specific reduction of A beta-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J. Neurosci. Res. 70, 493-500 (2002).
9. Iwata, N. et al. Metabolic regulation of brain Ab by neprilysin. Science 292, 1550-1552 (2001).
10. Liu, Y. et al. Circulating neprilysin clears brain amyloid. Mol. Cell. Neurosci. 45, 101-107 (2010).
11. Guan, H. et al. Peripherally expressed neprilysin reduces brain amyloid burden: a novel approach for treating Alzheimer's disease. J. Neurosci. Res. 87, 1462-1473 (2009).
12. Park, M. H. et al. Recombinant soluble neprilysin reduces amyloid-beta accumulation and improves memory impairment in Alzheimer's disease mice. Brain Res. 1529, 113-124 (2013).
13. El-Amouri, S. S. et al. Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease. Am. J. Pathol. 172, 1342-1354 (2008).
14. Hemming, M. L. et al. Reducing amyloid plaque burden via ex vivo gene delivery of an Aβ-degrading protease: A novel therapeutic approach to Alzheimer disease. PLoS Med. 4, e262 (2007).
15. Blurton-Jones, M. et al. Neural stem cells genetically-modified to express neprilysin reduce pathology in Alzheimer transgenic models. Stem Cell Res. Ther. 5, 46 (2014).
16. Ayoub, S. & Melzig, M. F. Influence of selected natural products on neutral endopeptidase activity and β-amyloid production in SKN-SH cells. Pharmaceut. Biol. 46, 425-432 (2008).
17. Eisele, Y. S. et al. Gleevec increases levels of the amyloid precursor protein intracellular domain and of the amyloid-β-degrading enzyme neprilysin. Mol. Biol. Cell 18, 3591-3600 (2007).
18. Klein, C. et al. The neuroprotector kynurenic acid increases neuronal cell survival through neprilysin induction. Neuropharmacology 70, 254-260 (2013).
19. Chandra, V. et al. Incidence of Alzheimer's disease in a rural community in India: the Indo-US study. Neurology 57, 985-989 (2001).
20. Ganguli, M. et al. Apolipoprotein E polymorphism and Alzheimer disease: The Indo-US cross-national dementia study. Arch. Neurol. 57, 824-830 (2000).
21. Brondino, N. et al. Curcumin as a therapeutic agent in dementia: A mini systematic review of human studies. Sci. World J. 2014, 174282 (2014).
22. Aggarwal, B. B., Sundaram, C., Malani, N. & Ichikawa, H. Curcumin: the Indian solid gold. Adv. Exp. Med. Biol. 595, 1-75 (2007).
23. Liao, K. K. et al. Curcuminoids promote neurite outgrowth in PC12 cells through MAPK/ERK-and PKC-dependent pathways. J. Agric. Food Chem. 60, 433-443 (2012).
24. Lim, G. P. et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 21, 8370-8377 (2001).
25. Wang, P. et al. Mechanisms and effects of curcumin on spatial learning and memory improvement in APPswe/PS1dE9 mice. J. Neurosci. Res. 92, 218-231 (2014).
26. Ahmed, T., Enam, S. A. & Gilani, A. H. Curcuminoids enhance memory in an amyloid-infused rat model of Alzheimer's disease. Neuroscience 169, 1296-1306 (2010).
27. Endo, H., Nikaido, Y., Nakadate, M., Ise, S. & Konno, H. Structure activity relationship study of curcumin analogues toward the amyloid-beta aggregation inhibitor. Bioorg. Med. Chem. Lett. 24, 5621-5626 (2014).
28. Chen, P. T. et al. A highly sensitive peptide substrate for detecting two Ab-degrading enzymes: neprilysin and insulin-degrading enzyme. J. Neurosci. Methods 190, 57-62 (2010).
29. Chen, P. T. et al. Design of peptide substrate for sensitively and specifically detecting two Aβ-degrading enzymes: neprilysin and angiotensin-converting enzyme. PLoS One 11, e0153360 (2016).
30. Li, W. et al. Structure elucidation and NMR assignments for curcuminoids from the rhizomes of Curcuma longa. Magn. Reson. Chem. 47, 902-908 (2009).
31. Wei, Q. Y., Chen, W. F., Zhou, B., Yang, L. & Liu, Z. L. Inhibition of lipid peroxidation and protein oxidation in rat liver mitochondria by curcumin and its analogues. Biochim. Biophys. Acta 1760, 70-77 (2006).
32. Begum, A. N. et al. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. J. Pharmacol. Exp. Ther. 326, 196-208 (2008).
33. Yang, F. et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280, 5892-5901 (2005).
34. Yasojima, K., McGeer, E. G. & McGeer, P. L. Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. Brain Res. 919, 115-121 (2001).
35. Uematsu, F., Takahashi, M., Yoshida, M., Igarashi, M. & Nakae, D. Methylation of neutral endopeptidase 24.11 promoter in rat hepatocellular carcinoma. Cancer Sci 97, 611-617 (2006).
36. Usmani, B. A. et al. Methylation of the neutral endopeptidase gene promoter in human prostate cancers. Clin. Cancer Res. 6, 1664-1670 (2000).
37. Deng, Y. et al. Curcumin inhibits the AKT/NF-kappaB signaling via CpG demethylation of the promoter and restoration of NEP in the N2a cell line. AAPS J 16, 649-657 (2014).
38. Lim, C. S. & Alkon, D. L. PKCepsilon promotes HuD-mediated neprilysin mRNA stability and enhances neprilysin-induced Abeta degradation in brain neurons. PLoS One 9, e97756 (2014).
39. Kakiya, N. et al. Cell surface expression of the major amyloid-beta peptide (Abeta)-degrading enzyme, neprilysin, depends on phosphorylation by mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) and dephosphorylation by protein phosphatase 1a. J. Biol. Chem. 287, 29362-29372 (2012).
40. Saito, T. et al. Somatostatin regulates brain amyloid b peptide Ab42 through modulation of proteolytic degradation. Nat. Med. 11, 434-439 (2005).
41. Khanna, S. et al. Neuroprotective and antiinflammatory properties of a novel demethylated curcuminoid. Antioxid. Redox Signal. 11, 449-468 (2009).
42. Chen, W. F., Deng, S. L., Zhou, B., Yang, L. & Liu, Z. L. Curcumin and its analogues as potent inhibitors of low density lipoprotein oxidation: H-atom abstraction from the phenolic groups and possible involvement of the 4-hydroxy-3-methoxyphenyl groups. Free Radic. Biol. Med. 40, 526-535 (2006).
43. Venkateswarlu, S., Ramachandra, M. S. & Subbaraju, G. V. Synthesis and biological evaluation of polyhydroxycurcuminoids. Bioorg. Med. Chem. 13, 6374-6380 (2005).
44. Borchelt, D. R. et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17, 1005-1013 (1996).
45. Jankowsky, J. L. et al. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol. Eng. 17, 157-165 (2001).
46. Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nature Methods 9, 671-675 (2012).
47. Frommer, M. et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl. Acad. Sci. USA 89, 1827-1831 (1992).